Summary
The US FDA has approved an at-home starter dose for Eisai and Biogen's Alzheimer's drug, Leqembi, allowing patients to self-administer subcutaneous injections. This approval improves access to treatment and differentiates Leqembi from competitor Kisunla, which requires infusion-only administration.
Turn this story into an image post, carousel, video, audio reel, blog, and more — all from HyperFast News.
Pick a story, apply your brand template, and publish polished graphics to Facebook, Instagram, LinkedIn, and more — without opening a design tool.
Create Image PostDescribe the story, headline, colors, and style you want.
Try Prompt to PostCombine branded news graphics with narration — from your audio library, a live recording, or AI text-to-speech — and share as engaging short-form content.
Create Audio PostUpload your footage, apply a video template with baked-in headlines, add optional audio, and schedule posts across every connected social channel.
Create Video PostCombine several news items into a single swipeable carousel post — with a shared title, unified caption, and per-slide template content for maximum engagement.
Create CarouselUpload your media, craft the perfect caption with AI assistance, preview on every platform, and schedule posts for the exact moment your audience is online.
Schedule a PostTransform breaking news into long-form, SEO-optimized blog posts with AI writing, a rich text editor, featured images, and one-click social image post creation.
Create Blog PostTurn any news article into a professional anchor video with AI-generated presenters, natural voice narration, and lip-sync animation — no studio, no crew, no wait.
Learn moreAbout the public HyperFast News news feed powered by NewsEngine.
Purpose-built AI tools and business automation workflows for publishers, stores, agencies, and brands.
Products
© 2026 HyperFast. All Rights Reserved.
An initiative of Xzect Labs Private Limited
FDA Approves This Year's Covid Vaccines; Rollout Expected in Days
14 Sept 2026, 6:04 pm · News
FDA Approves Landmark Pancreatic Cancer Drug Showing Improved Survival
14 Sept 2026, 6:04 pm · News
FDA Approves Daraxonrasib, New Pancreatic Cancer Drug Showing Extended Survival
14 Sept 2026, 6:04 pm · News
FDA Approves World's First Dual-Sensor CGM for Ketones and Blood Sugar
14 Sept 2026, 6:04 pm · News
FDA Gives Expedited Approval to New Groundbreaking Pancreatic Cancer Drug
14 Sept 2026, 6:04 pm · News
FDA Approves Daraxonrasib, Poised to Transform Pancreatic Cancer Treatment
14 Sept 2026, 6:04 pm · News
